Curemark is a biopharmaceutical company focused on the development of novel therapies to treat serious diseases for which there are limited treatment options. Our product candidates offer innovative therapeutic approaches and may have the potential to provide significant advantages relative to current therapies. Curemark has over 200 worldwide patents issued and continues to extend its platform technology across multiple disease states. Curemark’s lead drug candidate, CM-AT, has received “Fast Track” designation from the U.S. Food and Drug Administration (FDA).
Company Website: www.curemark.com
Email: [email protected]